Fernando Caas, Ctedra de Bioqumica y Biologa Molecular, Facultad de Ciencias Mdicas, INICSA (CONICET-Universidad Nacional de Crdoba), Crdoba 5000, Argentina
It is a test of whether metabolic therapy can change disease patterns that used to be discussed separately from obesity medicine
This substantial difference persisted across demographic subgroups and tumor types, suggesting therapeutic benefits beyond metabolic management
[DOI] [PubMed] [Google Scholar] Leth-Larsen R., Lund R
For payloads requiring high stability, such as those that degrade or deactivate easily in the bloodstream, non-cleavable linkers can better ensure drug integrity and safety during delivery
Based on REDEFINE trial populations and the NDA submission terms, expected eligibility criteria are: BMI 30 , or BMI 27 with at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea Adults 18 years or older Not pregnant or breastfeeding Contraindications will likely include: personal or family history of MTC or MEN 2 syndrome, prior serious allergic reaction to semaglutide or cagrilintide, and active pancreatitis
